Monoclonal Antibody Therapy

Novel COVID-19 monoclonal antibody therapy

Due to increased incidence of variant forms of SARS-CoV-2 which have differing resistance to monoclonal antibody therapies, as of August 27, 2021, it is now recommended that Utah providers utilize any of the following formulations, if access to these products are available:

  • casirivimab-imdevimab (Regeneron)
  • sotrovimab
  • bamlanivimab and etesevimab

Products approved by FDA for use in Utah will be updated based on changes to CDC, FDA, and HHS guidance.

In addition to Eligibility Criteria, there are a number of Inclusion Criteria as defined by the EUA that specify who is eligible for this novel treatment.

For more information about monoclonal antibody therapy, click here.


COVID-19 Research Studies and Trials

Several Utah-based clinical trials and studies are underway.  Some of these are listed below:

Intermountain Healthcare: ACTIV-4. This study is part of a national effort to determine if blood thinners can help prevent blood clots that can cause stroke, heart attacks, blood clots in the lungs (PE), blood clots in the legs (DVT), or even admission to the hospital in people with COVID-19 who are not initially admitted to the hospital. 

University of Utah: covidplasmatrial.org, 801-587-7573. This study will test whether a transfusion of plasma that has antibodies from persons who have recovered from COVID-19 is a good treatment for patients with early COVID-19 illness. Getting plasma with COVID-19 antibodies may protect us against a severe COVID-19 infection, but we first need to conduct this study to know for sure. The study involves one plasma infusion within a day of enrollment with follow-up visits to a nearby facility (physical exam, swab test, lab tests) and telephone calls over 90 days and a symptom diary you fill out between visits.

University of Utah: covidplasmatrial.org, 801-587-7573.
This study will test whether an infusion of plasma containing antibodies from recovered people can prevent uninfected people in a high-risk situation from developing COVID-19. If the trial proves to be successful, this treatment may help other people, who get exposed to the disease in the future, to not develop symptoms and possibly reduce the need for hospitalization. The study involves one plasma infusion at enrollment with follow-up visits to a nearby facility (physical exam, swab test, lab tests) and telephone calls over 90 days.

STOP COVID 2: https://stopcovidtrial.wustl.edu/, COVIDstudy@hsc.utah.edu, 385-722-4597.
STOP COVID Trial is a randomized controlled trial that aims to help slow the progression of COVID-19 symptoms in symptomatic patients in the United States. The study is contactless meaning volunteers may participate without leaving their home. Medication and study supplies are delivered by a courier or shipped overnight. We hope our study will demonstrate whether or not taking a medication, fluvoxamine, will help to prevent worsening of symptoms and prevent hospitalization.

UTAH ONE: https://utahcovidtrialsinfo.utahdcc.org/,COVIDstudy@hsc.utah.edu, 385-722-4597. This research study is designed to test possible treatments for COVID-19 and should help us better understand the virus and if Hydroxychloroquine might be a good treatment.This project will help us gain important information about how to better treat COVID-19. You will be asked to take either a study drug or a placebo, our team will deliver the pills and study supplies to your house. You will be asked to swab your throat for 14 days, answer questionnaires, and provide 3 blood samples.